A citation-based method for searching scientific literature

Jes Olesen, Hans-Christoph Diener, Ingo W Husstedt, Peter J Goadsby, David Hall, Ulrich Meier, Stephane Pollentier, Lynna M Lesko. N Engl J Med 2004
Times Cited: 868







List of co-cited articles
956 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathophysiology of Migraine: A Disorder of Sensory Processing.
Peter J Goadsby, Philip R Holland, Margarida Martins-Oliveira, Jan Hoffmann, Christoph Schankin, Simon Akerman. Physiol Rev 2017
667
33


CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Lars Edvinsson, Kristian Agmund Haanes, Karin Warfvinge, Diana N Krause. Nat Rev Neurol 2018
357
32

CGRP may play a causative role in migraine.
L H Lassen, P A Haderslev, V B Jacobsen, H K Iversen, B Sperling, J Olesen. Cephalalgia 2002
636
30

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Richard B Lipton, David W Dodick, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Armin Szegedi, Joel M Trugman. JAMA 2019
105
28

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Tiffini Voss, Richard B Lipton, David W Dodick, Nicole Dupre, Joy Yang Ge, Robert Bachman, Christopher Assaid, Sheena K Aurora, David Michelson. Cephalalgia 2016
152
27

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.
David J Hewitt, Sheena K Aurora, David W Dodick, Peter J Goadsby, Yang Joy Ge, Robert Bachman, Donna Taraborelli, Xiaoyin Fan, Christopher Assaid, Christopher Lines,[...]. Cephalalgia 2011
196
27

Ubrogepant for the Treatment of Migraine.
David W Dodick, Richard B Lipton, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Joel M Trugman, Armin Szegedi. N Engl J Med 2019
126
27



BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Ronald Marcus, Peter J Goadsby, David Dodick, David Stock, George Manos, Tanya Z Fischer. Cephalalgia 2014
171
25

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.
T W Ho, L K Mannix, X Fan, C Assaid, C Furtek, C J Jones, C R Lines, A M Rapoport. Neurology 2008
346
24

A Controlled Trial of Erenumab for Episodic Migraine.
Peter J Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Feng Zhang, Sandhya Sapra, Hernan Picard, Daniel D Mikol, Robert A Lenz. N Engl J Med 2017
388
24

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Richard B Lipton, Robert Croop, Elyse G Stock, David A Stock, Beth A Morris, Marianne Frost, Gene M Dubowchik, Charles M Conway, Vladimir Coric, Peter J Goadsby. N Engl J Med 2019
120
24

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock, Vladimir Coric, Richard B Lipton. Lancet 2019
115
24

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Tony W Ho, Michel D Ferrari, David W Dodick, Vince Galet, James Kost, Xiaoyin Fan, Heather Leibensperger, Samar Froman, Christopher Assaid, Christopher Lines,[...]. Lancet 2008
412
23

Fremanezumab for the Preventive Treatment of Chronic Migraine.
Stephen D Silberstein, David W Dodick, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi. N Engl J Med 2017
320
23

Calcitonin gene-related peptide: physiology and pathophysiology.
F A Russell, R King, S-J Smillie, X Kodji, S D Brain. Physiol Rev 2014
515
22

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
Tony W Ho, Kathryn M Connor, Ying Zhang, Eric Pearlman, Janelle Koppenhaver, Xiaoyin Fan, Christopher Lines, Lars Edvinsson, Peter J Goadsby, David Michelson. Neurology 2014
160
22

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Dean Leonardi, Daniel Mikol, Robert Lenz. Lancet Neurol 2017
343
21

Randomized, controlled trial of telcagepant for the acute treatment of migraine.
K M Connor, R E Shapiro, H-C Diener, S Lucas, J Kost, X Fan, K Fei, C Assaid, C Lines, Tony W Ho. Neurology 2009
162
20

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Virginia L Stauffer, David W Dodick, Qi Zhang, Jeffrey N Carter, Jessica Ailani, Robert R Conley. JAMA Neurol 2018
222
20

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Vladimir Skljarevski, Manjit Matharu, Brian A Millen, Michael H Ossipov, Byung-Kun Kim, Jyun Yan Yang. Cephalalgia 2018
199
20

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
David W Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lanteri-Minet, Vera Osipova, Kerry Palmer, Hernan Picard, Daniel D Mikol, Robert A Lenz. Cephalalgia 2018
241
19

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Holland C Detke, Peter J Goadsby, Shufang Wang, Deborah I Friedman, Katherine J Selzler, Sheena K Aurora. Neurology 2018
204
19

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.
Hans-Christoph Diener, Piero Barbanti, Carl Dahlöf, Uwe Reuter, Julia Habeck, Jana Podhorna. Cephalalgia 2011
164
18

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
David W Dodick, Stephen D Silberstein, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi. JAMA 2018
204
17

Wiping Out CGRP: Potential Cardiovascular Risks.
Antoinette MaassenVanDenBrink, Joris Meijer, Carlos M Villalón, Michel D Ferrari. Trends Pharmacol Sci 2016
125
16

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.
Jakob Møller Hansen, Anne Werner Hauge, Jes Olesen, Messoud Ashina. Cephalalgia 2010
262
16


Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
Hong Sun, David W Dodick, Stephen Silberstein, Peter J Goadsby, Uwe Reuter, Messoud Ashina, Joel Saper, Roger Cady, Yun Chon, Julie Dietrich,[...]. Lancet Neurol 2016
228
16



Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Michel D Ferrari, Hans Christoph Diener, Xiaoping Ning, Maja Galic, Joshua M Cohen, Ronghua Yang, Matthias Mueller, Andrew H Ahn, Yael Carmeli Schwartz, Melissa Grozinski-Wolff,[...]. Lancet 2019
129
16

Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing.
M G Rosenfeld, J J Mermod, S G Amara, L W Swanson, P E Sawchenko, J Rivier, W W Vale, R M Evans. Nature 1983
15

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Eva Cernuda-Morollón, Davinia Larrosa, César Ramón, Juan Vega, Pablo Martínez-Camblor, Julio Pascual. Neurology 2013
215
15

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
David W Dodick, Peter J Goadsby, Stephen D Silberstein, Richard B Lipton, Jes Olesen, Messoud Ashina, Kerri Wilks, David Kudrow, Robin Kroll, Bruce Kohrman,[...]. Lancet Neurol 2014
244
15

Calcitonin gene-related peptide (CGRP): a new target for migraine.
Andrew F Russo. Annu Rev Pharmacol Toxicol 2015
183
14

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
H Doods, G Hallermayer, D Wu, M Entzeroth, K Rudolf, W Engel, W Eberlein. Br J Pharmacol 2000
363
14

Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.
Debbie L Hay, Michael L Garelja, David R Poyner, Christopher S Walker. Br J Pharmacol 2018
177
14

Migraine--current understanding and treatment.
Peter J Goadsby, Richard B Lipton, Michel D Ferrari. N Engl J Med 2002
13

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
David W Dodick, Peter J Goadsby, Egilius L H Spierings, Joel C Scherer, Steven P Sweeney, David S Grayzel. Lancet Neurol 2014
247
13


Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.
Tony W Ho, Andrew P Ho, Yang Joy Ge, Christopher Assaid, Regina Gottwald, E Anne MacGregor, Lisa K Mannix, Willebrordus P J van Oosterhout, Janelle Koppenhaver, Christopher Lines,[...]. Cephalalgia 2016
59
20

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
Licheng Shi, Sonya G Lehto, Dawn X D Zhu, Hong Sun, Jianhua Zhang, Brian P Smith, David C Immke, Kenneth D Wild, Cen Xu. J Pharmacol Exp Ther 2016
135
12

Migraine and the trigeminovascular system-40 years and counting.
Messoud Ashina, Jakob Møller Hansen, Thien Phu Do, Agustin Melo-Carrillo, Rami Burstein, Michael A Moskowitz. Lancet Neurol 2019
98
12

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
Messoud Ashina, Joel Saper, Roger Cady, Barbara A Schaeffler, David M Biondi, Joe Hirman, Susan Pederson, Brent Allan, Jeff Smith. Cephalalgia 2020
100
12


Gepants for the treatment of migraine.
Andrea Negro, Paolo Martelletti. Expert Opin Investig Drugs 2019
60
18

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion.
S Eftekhari, C A Salvatore, A Calamari, S A Kane, J Tajti, L Edvinsson. Neuroscience 2010
210
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.